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The reported experimental study was conducted to compare the effects of repeated daily oral doses of
curcuminoids (CLE) with metformin as potential antidepressants and analgesics. Effects of a single and
ten daily oral doses of CLE (5, 20, 80 mg/kg/day) and of 50 mg/kg/day metformin (MET) were compared
in mice hot plate test (HPT) for analgesics. On the 11th treatment day, all animals were subjected to foot
shock stress triggered hyperthermia test, and on the 12th treatment day to tail suspension test (TST) for
antidepressants. Immediately thereafter, their blood levels of glucose, insulin and cortisol were quan-
tiﬁed. Dose dependent analgesic activity of CLE was observed in HPT, whereas the metformin dose tested
suppressed only pain hypersensitivity in the test. But statistically signiﬁcant effects of both of them were
observed in TST, and both of them also afforded protections against body weight loss and slight elevation
in core temperatures induced by daily handling and repeated testing. CLE or metformin had no signif-
icant effects in foot shock stress triggered transient hyperthermic responses or on blood glucose, insulin
and cortisol levels. Reported results reveal that curcuminoids as well as metformin are stress response
modiﬁers with antidepressants like activities, but only low dose curcuminoids possess centrally acting
analgesics like activities. They suggest that the bio-assay system used in this study is well suited for
identifying curcuminoids like plant metabolites with analgesic and anti-stress activities, and that low
dose curcuminoids are more effective as analgesics than low dose metformin.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Central hypersensitivity to pain is often encountered in patients
suffering from chronic inﬂammatory diseases as well as diverse
spectrums of somatic symptom disorders.1,2 In traditionally known
Indian and Chinese systems of medicine and health care, turmeric
(Curcuma longa rhizomes) is often used for prevention and cure of: þ91 542 2368428.
.ac.in (S. Verma), deepak@
ralremedy.com (A. Agarwal),
iitbhu.ac.in (V. Kumar).
for Food and Biomolecules,
tories, Dr. Willmar Schwabe
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).
et al., Effects of turmeric curc
edicine (2016), http://dx.dosuch medical conditions. Curcumin and structurally analogous
diarylheptanoids encountered in turmeric, often collectively
referred to as turmeric curcuminoids, are now attracting consid-
erable attention of modern drug discoverers as therapeutic leads
potentially useful for prevention and cure of chronic diseases
commonly associated with mental health problems and central
sensitivity to pain,3,4 and number of reports reafﬁrming anti-
nociceptive effects of curcumin and other turmeric derived prod-
ucts in animal models and clinical trials have continued to increase
since late decades of the 20th century.5,6 It has often been sug-
gested also that curcuminoids formulations or their derivative and
analogs with improved bioavailability and adverse effect potentials
could be universally more acceptable and reliable therapeutic al-
ternatives for prevention and cure of numerous chronic diseases,
including cancer and Alzheimer's disease.3,7,8 Such suggestions
often neglect that like numerous non-systemic9 or covalentrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
uminoids and metformin against central sensitivity to pain in mice,
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dictors of their therapeutic potentials or effectiveness.
Oral bioavailability studies conducted with curcuminoids have
consistently revealed that even after very high oral doses (up to 1 g/
kg) their observed blood levels are often undetectable.12,13 On the
other hand, it has often been reported that low oral doses of cur-
cumin possess antidepressant and stress response suppressing ef-
fects in laboratory rodents.14e16 A report on dose dependant anti-
nociceptive effects of curcumin after its single fairly low oral
doses has appeared also.17 Other dose ﬁnding studies have sug-
gested though, that oral 500 mg/kg curcumin could be its optimal
pharmacologically interesting dose in laboratory animals.18 There-
fore, in the realm of our ongoing psychopharmacological studies
with traditionally known herbal remedies and their bioactive
constituents19 we used curcumin and diverse types of curcumi-
noids enriched turmeric extracts to deﬁne their stress response
suppressing dose ranges and dosing regimen.20,21 They have
reconﬁrmed that repeated daily oral 5 mg/kg curcumin or turmeric
curcuminoids are high enough for increasing stress resistance in
mice and have revealed that several low dose effects of turmeric
curcuminoids are qualitatively analogous those of metformin and
diverse other food chemicals commonly consumed with every day
meals.22e26 Metformin is currently the antidiabetic drug of ﬁrst
choice for prevention and cure of diverse spectrums of comorbid-
ities associated with diabesity27 and it is also often used for treat-
ments of neuropathic pain.28 Numerous, but not all, therapeutically
interesting bioactivities of metformin known to date29 are quite
analogous to those of curcuminoids, and it has been reported also
that repeated daily oral curcumin administrations also suppresses
neuropathic pain in diabetic animals.30,31
However, like in numerous pharmacological studies with cur-
cumin and turmeric curcuminoids, most preclinical studied
revealing their no-conceptive potentials were conducted with their
relatively high doses and arbitrarily chosen dosing regimen.5
Therefore, the question whether daily oral intake of lower stress
resistance promoting or adaptogenic doses of turmeric curcumi-
noids could also suppress central hypersensitivity to pain still
remain open, or can be speculatively answered only. Results of an
experiment conducted to more rationally answering this question
has been described and discussed in this communication. Impli-
cation of the preclinical observation made to date with low dose
curcuminoids for better understanding of Ayurvedic concepts of
nutritional therapies or for more rational medicinal uses of
turmeric curcuminoids are also pointed out in this article.
2. Materials and methods
2.1. Animals
Swiss albino male mice (20 ± 5 g) obtained from the Central
Animal House of the Institute of Medical Sciences, Banaras Hindu
University, Varanasi, India (Registration Number: 542/AB/CPCSEA)
were housed in groups of six in polypropylene cages at an ambient
temperature of 25 ± 1 C and 45e55% relative humidity, with a
12:12 h light/dark cycle. They were always provided with com-
mercial food pellets andwater ad libitum, andwere acclimatized for
at least 1 week before using them for the experiments. Animals
used in this study were pre-selected for their pain sensitivity in the
hot plate test described later. For such purposes, reaction time of
animals on a hot plate maintained at 55 ± 1 C were recorded and
only those mice reacting within 15 s on the hot plate and which did
not show large variation when tested on four separate occasions
(each 15 min apart), were randomly allotted to different experi-
mental groups. Principles of laboratory animal care (NIH publica-
tion number 85-23, revised in 1985) guidelines were alwaysPlease cite this article in press as: Verma S, et al., Effects of turmeric cur
Journal of Traditional and Complementary Medicine (2016), http://dx.dofollowed, and prior approval from the Central Animal Ethical
Committee of the University (CAECU) was taken for this study
protocol (Dean/2014/CAEC/602, dated 30-05-2014).
2.2. Plant extract and other material used
The C. longa rhizome extract (CLE) highly enriched in turmeric
curcuminoids (95.49%, w/w) used in this study was generously
supplied by R&D Center of Natural Remedies Pvt. Ltd., Bengaluru,
India. HPLC chromatogram of CLE is shown in Fig.1. As quantiﬁed by
the USP 37-NF32 method, CLE contained curcumin (>77.94%, w/w),
demethoxycurcumin (>15.03%, w/w) and bisdemethoxycurcumin
(>2.52%, w/w), Metformin (Ranbaxy Laboratories, Gurgaon, India),
carboxymethyl cellulose (CMC) (Central Drug House, New Delhi,
India) and other chemicals and reagents used in this study were of
highest purity commercially available in India.
2.3. Animal grouping and drug treatments
Six groups of six animals each were randomly allotted to
different experimental groups. Two of them used as controls viz.
CON þ HPT (subjected to hot plate test; i.e. HPT) and CON  HPT
(not subjected to HPT) were treated orally with the vehicle (0.3%
CMC; 10 ml/kg/day) for 11 consecutive days. The four others were
similarly treated either with 50 mg/kg/day metformin or with 5
or 20 or 80 mg/kg/day CLE. Except for one of the CMC treated
control groups (CON  HPT), all others were subjected to hot
plate test on days 1, 5, 7, and 10 of the experiment. For oral ad-
ministrations, metformin and CLE were suspended in 0.3% CMC.
All tests were conducted one hour after the day's oral treatments
and all oral treatments on all observational days were given after
recording their body weights and rectal temperatures. Further
details of the experimental procedure used are graphically sum-
marized in Fig. 2.
2.4. Hot plate test (HTP)
One hour after days treatment, individual mice of a group was
gently placed on a hot plate maintained at 55 ± 1 C and its reaction
time (in seconds) for forepaw licking or jumping (whichever
occurred ﬁrst) were recorded.32 Immediately thereafter, the animal
was placed back in its home cage, and 10 min thereafter its rectal
temperature was recorded again. All rectal temperatures were
recorded using a calibrated rectal probe and electronic thermom-
eter. The numerical difference between the basal rectal tempera-
ture of an animal and its rectal temperature recorded 10 min after
the hot plate test was calculated and used as an index for hot plate
test induced hyperthermic response of the animal.
2.5. Foot shock stress induced hyperthermia test
All experimental groups were subjected to this test on the 11th
day of the experiment. The experimental procedure used has been
described in details elsewhere.21 In short, individual mouse of a
group was placed in a black box (24  29  40 cm) with a grid
ﬂoor for 1 min. After 10 s of its stay in the box, ﬁve consecutive
electric foot shocks of 2 mA at 10 s intervals were given through
the grid ﬂoor (2 mA, 50 Hz of 2 ms duration). Immediately
thereafter, the animal was placed back in its home cage and
10 min thereafter its rectal temperature was recorded again. Dif-
ference between the rectal temperature of the animal recorded
10 min after the foot shock stress and that of its basal one of that
day was considered to be its foot shock stress induced hyper-
thermic response.cuminoids and metformin against central sensitivity to pain in mice,
i.org/10.1016/j.jtcme.2016.04.001
Fig. 1. HPLC chromatogram of curcuminoids (CLE).
Fig. 2. Graphical representation of experimental procedure used.
S. Verma et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e7 32.6. Tail suspension test and blood glucose, insulin and cortisol
estimations
Using the procedure described earlier,21,22 the tail suspension
test for assessingdepressive state of animals33was conducted on the
12th day of the experiment. In short, one hour after recording its
body weight and basal rectal temperature, an individual mouse of a
groupwas hungupside downon its tail (using adhesive tapes placed
at approximately 1 cmdistance from its tail tip) on a horizontal wire
placed 50 cm above the ﬂoor. After initial vigorous movements, the
mouse assumed an immobile posture and the period of immobility
during a 5 min observation period was recorded. Immediately after
the test, blood samples of the animals were collected by retro-
orbital venous plexus sampling method and blood plasma was
separated by cold centrifugation. Using appropriate test kits and
instructions of the manufacturers, plasma glucose (Autospan
Glucose test kit; BeaconDiagnostic Pvt. Ltd., Navasari, India), insulin
(ELISA test kit; DRG Instruments GmbH, Germany) and cortisol
(ELISA kit; Enzo Life Sciences; PA, USA) were quantiﬁed.
2.7. Statistical analysis
Mean ± standard error of mean (SEM) was calculated for the
observed values in each experimental group. Statistical analysisPlease cite this article in press as: Verma S, et al., Effects of turmeric curc
Journal of Traditional and Complementary Medicine (2016), http://dx.dowas performed by one way analysis of variance (ANOVA) followed
by StudenteNewmaneKeuls multiple comparison test, two way
ANOVA followed by Bonferroni post hoc test. GraphPad Prism-5
(GraphPad Software Inc., La Jolla, California, USA) was used for
statistical analysis. Origin-Pro 8 (OriginLab Corporation, Massa-
chusetts, USA) software was used for graphs representation. p-
value less than 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Body weights and core temperatures
These results are summarized in the Fig. 3a and b. Mean body
weights of both the control groups decrease gradually during the
course of the experiment, whereas their mean basal rectal tem-
peratures increased gradually. Rates of these changes during the
course of the experiments in both the control groups were quite
similar. These stress triggered alterations caused by daily handling
and occasional testing were not observed in the CLE or metformin
treated groups. Even 5 mg daily CLE dose was highly effective in
compensating both these alterations. These efﬁcacies of 50 mg/kg/
day metformin for antagonizing body weight loss and core tem-
perature elevation were almost identical to those of 5 mg/kg/day
and 20 mg/kg/day CLE respectively, and those of the 20 and 80 mg/uminoids and metformin against central sensitivity to pain in mice,
i.org/10.1016/j.jtcme.2016.04.001
Fig. 3. Effects of thermal stimuli induced stress on a) body weight and b) basal rectal temperature of male mice treated with curcuminoids (CLE) and metformin (MET). CON þ HPT
(Hot plate control), CON  HPT (normal control). Values are mean ± SEM, n ¼ 6. *Denotes statistically signiﬁcant difference (Two way ANOVA followed by Bonferroni post hoc test)
relative to CON þ HPT group (*p < 0.05).
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ations were almost identical.
3.2. Hot plate test
Results summarized in Fig. 4a reveal that onehour after theirﬁrst
oral doses neither metformin nor CLE had any signiﬁcant effects on
themean reaction time ofmalemice preselected for their sensitivity
to pain responses in the hot plate test. Mean reaction time of the
vehicle treated control group (CONþHPT) continued to decrease on
the 5th and subsequent observational days, whereas those of the
CLE treated ones steadily increased during the course of the
experiment. Analogous observed effects of metformin treatments
were qualitative similar to those of CLE, but the observed effects of
even the lowest tested daily CLE dose (5 mg/kg/day) on the 5th and
subsequent observational days were somewhat higher than that of
metformin dose (50 mg/kg/day) tested. It is apparent from the
calculated values summarized in Fig. 4b that pain response sensi-
tivity of the metformin treated group remained almost constant on
all observational days whereas that of CLE continued to increase
dose dependently with increasing numbers of treatment days.
3.3. Hot plate test and foot shock stress triggered hyperthermic
responses
Core temperatures of animals recorded 10 min after the hot
plate test were always slightly higher than their basal one of theFig. 4. Effects of curcuminoids (CLE) and metformin (MET) on a) mean hot plate reaction time
plate control). Values aremean± SEM, n¼ 6. *Denotes statistically signiﬁcant difference (Twow
Please cite this article in press as: Verma S, et al., Effects of turmeric cur
Journal of Traditional and Complementary Medicine (2016), http://dx.doday. These results summarized in Fig. 5 reveal that magnitude of
this hot plate testing procedure triggered transient hyperthermic
responses in the vehicle treated control group (CON þ HPT)
increased somewhat during the course of the experiment, whereas
those of the CLE or metformin treated ones remained almost con-
stant on all observational days. On the ﬁst observational day
magnitude of this response of the CLE or metformin treated groups
were statistically not signiﬁcantly different than the control group.
Statistically signiﬁcant effect of metformin (50 mg/kg/day) treat-
ment on this response was observed only on the 7th treatment day
and that of the highest tested CLE dose (80 mg/kg/day) on the 10th
observational day. Transient hyperthermic responses triggered by
less than 1 min exposures of the animals to foot shock stress on the
11th treatment day were much higher in magnitude than those
triggered by hot plate test on earlier observational days. Results of
the foot shock stress induced hyperthermia test summarized in
Table 1 did not reveal any statistically signiﬁcant effects of CLE or
metformin treatments in this test.
3.4. Tail suspension test and plasma glucose, insulin and cortisol
levels
After 11 daily oral treatments, all tested doses of CLE and met-
formin signiﬁcantly lowered the immobility period of mice in this
test. These results summarized in Fig. 6 revealed that efﬁcacy of CLE
increased dose dependently and that the efﬁcacy of the lowest
tested daily dose (5 mg/kg/day for eleven consecutive days) of CLEand b) hot plate reaction time difference of male mice respect to day 1. CONþ HPT (Hot
ayANOVA followed byBonferroni post hoc test) relative to CONþHPTgroup (*p< 0.05).
cuminoids and metformin against central sensitivity to pain in mice,
i.org/10.1016/j.jtcme.2016.04.001
Fig. 5. Thermal stimuli induced hyperthermia in male mice treated with curcuminoids
(CLE) and metformin (MET). CON þ HPT (Hot plate control). Values are mean ± SEM,
n ¼ 6. *Denotes statistically signiﬁcant difference (Two way ANOVA followed by
Bonferroni post hoc test) relative to CON þ HPT group (*p < 0.05).
Table 1
Effects of 11 daily oral doses of curcuminoids (CLE) and metformin (MET) on foot
shock stress induced transient hyperthermic response in male mice.
Treatment groups Rectal temperature (C)
Before After Difference
CON þ HPT 37.60 ± 0.09 38.32 ± 0.07a 0.72 ± 0.04
CON  HPT 37.42 ± 0.15 38.08 ± 0.16a 0.67 ± 0.03
CLE (5 mg/kg) 37.18 ± 0.11 37.82 ± 0.11a 0.63 ± 0.06
CLE (20 mg/kg) 36.87 ± 0.15 37.43 ± 0.13a 0.57 ± 0.03
CLE (80 mg/kg) 36.88 ± 0.09 37.42 ± 0.08a 0.53 ± 0.05
MET (50 mg/kg) 36.85 ± 0.09 37.45 ± 0.12a 0.60 ± 0.06
Values are mean ± SEM, n ¼ 6.
a Denotes statically signiﬁcant difference (t-test; p < 0.05) between the mean
values of the group recorded before and 10 min after exposure to foot shock stress.
Fig. 6. Effects of curcuminoids (CLE) and metformin (MET) in tail suspension test on
day 12. CON þ HPT (Hot plate control), CON  HPT (normal control). Values are
mean ± SEM, n ¼ 6. *Denotes statistically signiﬁcant difference (ANOVA) relative to
CON þ HPT group (*p < 0.05).
Fig. 7. Effects of curcuminoids (CLE) and metformin (MET) on plasma glucose level in
male mice. CON þ HPT (Hot plate control), CON  HPT (normal control). Values are
mean ± SEM (n ¼ 6). *Denotes statistically signiﬁcant difference (ANOVA) relative to
CON þ HPT group (*p < 0.05).
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plasma glucose levels of the control group subjected to hot plate
test (CON þ HPT) was statistically signiﬁcantly higher than the
other control group not subjected to the test (CON  HPT). These
mean values of the two groups were 94.18 ± 1.35 and 87.58 ± 1.02
respectively as shown in Fig. 7. However, mean plasma insulin or
cortisol levels of the CLE or metformin treated were not signiﬁ-
cantly different from those of the CON þ HPT group, and no sta-
tistically signiﬁcant differences between the plasma and cortisol
levels of the two control groups were observed (results not shown).Please cite this article in press as: Verma S, et al., Effects of turmeric curc
Journal of Traditional and Complementary Medicine (2016), http://dx.do4. Discussion
Reported observations revealing centrally acting analgesics like
effects of turmeric curcuminoids strongly suggest that regular
intake of their fairly low oral doses could be useful for suppressing
central hypersensitivity to pain triggered by repeated exposures to
peripheral noxious stimuli. They also add further experimental
evidence in support of our working hypothesis that curcuminoids
are non-systemic drugs like polyvalent bioactive agents, and that
they are regulators of digestive functions involved in controlling
body weights and temperature. Like in our earlier dose ﬁnding
experiments,20,21 maximal possible protective effects of CLE against
body weights changes and core temperature were observed even
after its lowest daily dose (5 mg/kg/day) tested. Interestingly
though, dose dependant efﬁcacy of CLE in prolonging reaction
times in hot plate test increased with increasing number of treat-
ment days, whereas even its highest tested daily dose (80 mg/kg/
day) had no protective effects against foot shock stress triggered
transient hyperthermic responses after its 11 daily treatments.
These ﬁndings, taken together with earlier observations21 revealing
that 10 daily 5 mg/kg oral doses of CLE are long and high enough for
suppressing foot shock stress triggered hyperthermic responses as
well as longer lasting alterations in body weight and core tem-
peratures triggered by daily handling and repeated testing20
strongly suggest that bioactivity proﬁles of CLE depend not only
on their daily oral doses and number of treatment days, but also on
the earlier stressful experiences of the test subjects. Since except for
the analgesic activities all other observed effects of CLE and met-
formin in this and in our earlier study were analogous, it seems
reasonable to assume that such is the case for metformin as well.
Animals used in this study were four times pre-exposed to 55 C
hot plate test for pre-selection purposes and the rate of alterations
in the body weights and basal core temperatures of animals of both
the control groups observed during the course of the experiment
were similar. Therefore, it is apparent that these long lasting al-
terations are not due to daily handling or testing procedures used
during the course of the described experiment only, and that they
are consequences, or late effects, of repeated pre-exposures of the
animals to hot plate during the pre-selection procedure. These
observations encourage us suggest that such preselected animals
are well suited not only for increasing the reliability and repro-
ducibility of pharmacological observations made in hot plate test,
but also for estimating possible effects of test agents on mild
experimental stress triggered alterations in body weights and core
temperatures.
The observations that 5 mg/kg daily oral doses CLE is its maxi-
mally effective ones in affording protection against repeateduminoids and metformin against central sensitivity to pain in mice,
i.org/10.1016/j.jtcme.2016.04.001
S. Verma et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e76exposures to hot plate or foot shock stress triggered alterations in
body weight and core temperature strongly suggest that turmeric
curcuminoids are more effective modulators of energy metabolism
and central pain sensitivity than the metformin dose tested. These
observations taken together with available information on oral
bioavailability and metabolic stability of curcuminoids12 suggest
that either the pharmacological site(s) of action involved in these
effects of curcuminoids reside inside the gastrointestinal tract, or
some of its bioactive intra-gastric metabolites are involved in its
observed effects. In any case, it remains certain that like metformin
and numerous other food phytochemical22e26 low dose curcumi-
noids are also modulators of brain functions and homeostatic
processes regulating bodyweight and core temperature changes, as
well as depressive state of rodents, triggered by external or envi-
ronmental stimuli. The observations that blood glucose, insulin,
and cortisol levels of CLE ormetformin treated animals werewithin
the ranges observed in vehicle treated control animals, might
suggest that biological processes and mechanisms regulating these
blood levels are not involved in their such effects. However, since
these observationsweremade only at one time point and at the end
of the experiment only, they are not very deﬁnitive evidences for
negating the possibility of their involvements in the modes of ac-
tions of the test agents. It remains certain though, that dose
dependant, and qualitatively metformin like, antidepressants like
efﬁcacy of CLE in tail suspension test persists 24 h after its last oral
doses, and that repeated daily tested doses of CLE, or of 50 mg/kg
metformin, have no long lasting effects on blood glucose, insulin,
and cortisol levels of male mice often subjected to hot plate and
other tests.
Efforts to pin point the modes of actions of curcuminoids have
revealed that curcuminoids increase phosphorylation of AMP-
activated protein kinase (AMPK) in hepatoma cells and that one
of the turmeric curcuminoids, i.e. curcumin, is several hundred
folds more effective than metformin in activating the downstream
targets of the kinase.34 AMPK is a nutrient and energy sensor
involved in maintenance of energy homeostasis regulating meta-
bolic responses to cellular stress.35e39 Therefore, it seems reason-
able to assume that observed high efﬁcacy of CLE in protecting
stress triggered alterations in body weight and core temperature is
mainly due to its ability to stimulate AMPK inside the gastroin-
testinal tract. However, the question whether or not other known
bioactivities of curcuminoids observed in cellular and other in vitro
models are also involved in often reported analgesics and antide-
pressants like efﬁcacies of curcuminoids5,40 still remain open or
speculative only.
Our observations clearly reveal, that analgesics and antide-
pressants like efﬁcacies of CLE observed after its 10 or more daily
doses increased with its increasing daily doses, whereas its
maximal possible protective effects against stress triggered
changes in body weight and core temperature were apparent even
after its lowest tested daily doses (5 mg/kg). These observations
strongly suggest that either bioavailability of curcuminoids and/or
of their metabolites increase with increasing numbers of treatment
days, or that their effectiveness to modulate the functions of
pharmacological targets other than AMPK are several folds lower.
Curcuminoids are extensively metabolized inside the gut,41 and
regular oral intake of curcuminoids alters gut microbial ecology and
functions.42 Moreover, they also possess antibacterial, antiviral, and
antifungal activities.43 Therefore, it could as well be that their
observed dose dependant anti-stress, analgesic and antidepressant
activities observed after their fairly loworal doses are mainly due to
slowly evolving and longer lasting effects of curcuminoids and/or
their metabolites on gut microbial ecology and functions.
Although crucial role of gut microbiota in regulating physical
and mental health status is now well recognized,44e46 as yet onlyPlease cite this article in press as: Verma S, et al., Effects of turmeric cur
Journal of Traditional and Complementary Medicine (2016), http://dx.dovery little concentrated efforts have been made to translate avail-
able preclinical information on curcuminoids and numerous other
food phytochemicals with bactericidal activities in terms of their
therapeutic potentials. Observations reported in this and in our
earlier reports encourage us suggest that the bioassay procedure
used in this study could be a feasible and cost effective one for such
purposes. Therefore, efforts to further pharmacological validate the
bioassay procedure using other phytochemicals and drugs with
microbicidal activities or modulating effects on AMPK can be
warranted. Such efforts will not only be helpful for better under-
standing of pharmacological principles behind traditionally known
dietary and herbal therapies, but also could eventually lead to novel
therapeutic leads and pharmacological targets urgently need for
discovering and developing functionally novel antidepressant
drugs with preventive effects against central hypersensitivity to
pain and metabolic disturbances.
It has often been suggested that both curcuminoids and met-
formin can be used for prevention and cure of diverse spectrums of
mental health problems and other co-morbidities commonly
associated with lifestyle disorders and aging,47e49 and that
turmeric could be an adjuvant diabetic therapy with metfor-
min.50,51 However, as yet no reports on possible pharmacological
interactions between lodes curcuminoids and metformin have
appeared. Encouraged by the observation reported in this
communication, efforts will now be made in our laboratories to
experimentally verify whether combinations of CLE and metformin
could have additive or synergistic effects or not. Results of these
efforts will not only be useful for more rational development of
polypills with metformin and curcuminoids, but also for better
understanding of pharmacological principles behind traditionally
known medicinal and healthcare uses of turmeric.
5. Conclusion
Both curcuminoids and metformin are orally active stress
response modiﬁers, but unlike metformin even very low doses of
curcuminoids can also prevent chronic stress triggered central
hypersensitivity to pain. The bio-assay system used in this study is
well suited for identifying such activities of herbal extracts and
their bioactive constituents, and also for better deﬁning of biolog-
ical interactions between them. Further efforts to identify the
bioactive constituents of other products derived from turmeric and
other traditionally known medicinal herbs using the bioassay
procedures reported in this study could lead to yet other structur-
ally and functionally novel drug leads for prevention and cure of
central sensitivity syndromes.
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